Immuneering Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.66 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.22.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.19, a 2.57% increase year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.11, a 3.32% increase year-over-year.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.71, a 15.05% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.19, a 9.89% decline from fiscal 2023.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $3.54, a 17.61% increase from fiscal 2022.
- Immuneering Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $3.01, a 0.00% change from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.66 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $2.22 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.71 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $2.84 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.28 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $3.19 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $3.19 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $3.19 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $3.19 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $3.54 10-K · filed 2024-03-01 | |||
| 2023-09-30 | $3.55 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $3.55 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $3.11 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $3.01 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $3.02 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $3.02 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $3.01 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $3.01 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $3.04 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $3.01 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |